GlassScriptPhysician profile
Emily H Harless
NPI 1306227566
$6,744.58
in general payments reported to CMS, 2019-2025
69 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,652 · 2022: $1,536 · 2023: $1,081 · 2024: $1,232 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,557.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.99 | 2021-2025 | |
| Lilly USA, LLC | $619.06 | 2021-2025 | Mounjaro, Zepbound, Amyvid |
| Astrazeneca Pharmaceuticals LP | $261.83 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Pfizer INC. | $227.84 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.59 | 2021-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $196.76 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $189.82 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $188.27 | 2021-2024 | Spravato, Xarelto |
| Eisai INC. | $186.93 | 2021-2024 | |
| Glaxosmithkline, LLC. | $163.83 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $146.64 | 2021-2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.56 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $139.00 | 2024-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $121.02 | 2021-2024 | Verquvo, Dificid |
| Amarin Pharma, INC. | $116.37 | 2021 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Harless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.